At the heart of Amgen’s commitment to biosimilars is our mission to serve patients. Quality biosimilars are anticipated to offer more treatment options for patients1—and we believe that we bring high-quality science to this new space in healthcare.
We want to help patients access the medicines they need. With increased availability of lower-cost biosimilars, patients have more options to choose the right medicine at the right time.
Reference: 1. The Center For Biosimilars. Biosimilars market is ripe for cost savings.
www.centerforbiosimilars.com/contributor/chad-pettit/2019/06/biosimilars-market-is-ripe-for-cost-savings. Accessed October 29, 2019.